We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Eva
McGrowder
eva.mcgrowder@icr.ac.uk
Dr
Eva
McGrowder
eva.mcgrowder@icr.ac.uk
Prof
Ros
Eeles
rosalind.eeles@icr.ac.uk
Malignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The i4i PRODICT® study has been developed to investigate the uptake and acceptability of the i4i PRODICT® test which combines both common and rare genetic changes (genetic variants) into one saliva-based DNA test to estimate a person's future risk of prostate cancer (PrCa) in people of varying ethnicities.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Other;
You can take part if:
You may not be able to take part if:
• Previous diagnosis of prostate cancer. • People of mixed ancestry • Previous diagnosis of cancer with a life-expectancy of less than five years. • Negative prostate biopsy within one year before recruitment. • Any significant psychological conditions that may be worsened or exacerbated by participation in the study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Eva
McGrowder
eva.mcgrowder@icr.ac.uk
Dr
Eva
McGrowder
eva.mcgrowder@icr.ac.uk
Prof
Ros
Eeles
rosalind.eeles@icr.ac.uk
The study is sponsored by Institute of Cancer Research: Royal Cancer Hospital and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 60072
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
